Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Bibliographic Details
Main Authors: Dent, Rebecca A, Lindeman, Geoffrey J, Clemons, Mark, Wildiers, Hans, Chan, Arlene, McCarthy, Nicole J, Singer, Christian F, Lowe, Elizabeth S, Watkins, Claire L, Carmichael, James
Format: Online
Language:English
Published: BioMed Central 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979135/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979135/

Similar Items